Literature DB >> 2810109

Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

D Paul1, K M Standifer, C E Inturrisi, G W Pasternak.   

Abstract

Morphine-6 beta-glucuronide is a major metabolite of morphine with potent analgesic actions. To define more fully the importance of this compound in morphine action, we have compared the analgesic actions of morphine and its 6 beta-glucuronide metabolite after both peripheral and central administration. Given s.c., morphine-6 beta-glucuronide elicited analgesia with an effect approximately twice that of morphine due, in part, to its long duration of action and also inhibited gastrointestinal motility. Both actions were easily reversed by naloxone (s.c.). However, when injected either i.c.v. or intrathecally, morphine-6 beta-glucuronide was approximately 90- and 650-fold more potent an analgesic than morphine, respectively. Whereas morphine in these studies was equipotent at both levels of the neuraxis as an analgesic, the 6 beta-glucuronide was approximately 5-fold more effective at the level of the spinal cord than supraspinally. The mu 1-selective antagonist naloxonazine blocked the analgesic effect of systemic and i.c.v. morphine-6 beta-glucuronide much as it blocked morphine, implying a role for mu1 receptors in these actions. Like morphine, morphine-6 beta-glucuronide analgesia after intrathecal injection was not sensitive to naloxonazine, suggesting a mu2 mechanism within the spinal cord. Together, these results imply that morphine-6 beta-glucuronide elicited its analgesic actions through the same receptor mechanisms as morphine. Mice highly tolerant to morphine after implantation of morphine pellets showed cross-tolerance to morphine-6 beta-glucuronide (s.c.). The high potency of morphine-6 beta-glucuronide strongly suggests that this metabolite plays an important role in morphine's actions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810109

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  64 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 4.  Strong opioids in pediatric palliative medicine.

Authors:  Richard D W Hain; Angela Miser; Mary Devins; W Hamish B Wallace
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 6.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

7.  Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat.

Authors:  Maria Meringolo; Valentina Brusadin; Maria T De Luca; Christian Montanari; Christian L Montanari; Letizia Antonilli; Paolo Nencini; Aldo Badiani
Journal:  Psychopharmacology (Berl)       Date:  2011-10-21       Impact factor: 4.530

8.  [The role of morphine-6-glucuronide during longterm administration of morphine.].

Authors:  M Prokopek; A Ziegler
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

9.  [The estimation of the i.m. morphine-equivalent in cancer pain treatment with different opioids or different routes of administrations. Practical meaning and limitations.].

Authors:  J Jage; R K Portenoy; K M Foley
Journal:  Schmerz       Date:  1990-06       Impact factor: 1.107

Review 10.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.